GlassScriptPhysician profile
Leslie Wilbanks
NPI 1154550994
$2,409.51
in general payments reported to CMS, 2019-2025
23 companies · $676 in 2025
The $676 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $61.42 · 2021: $23.68 · 2022: $214 · 2023: $161 · 2024: $915 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $473.78 | 2021-2025 | Ubrelvy |
| Jazz Pharmaceuticals INC. | $357.72 | 2022-2025 | |
| Catalyst Pharmaceuticals, INC. | $221.50 | 2024-2025 | |
| Pfizer INC. | $162.12 | 2023-2025 | |
| Microtransponder, INC. | $161.65 | 2024 | |
| Janssen Scientific Affairs, LLC | $148.99 | 2025 | |
| W. L. Gore & Associates, INC. | $137.66 | 2019 | |
| Biogen, INC. | $107.76 | 2023-2025 | Vumerity, Tysabri |
| Mdd US Operations, LLC | $74.48 | 2022-2023 | Apokyn |
| Sunovion Pharmaceuticals INC. | $71.62 | 2019-2020 | |
| Emd Serono, INC. | $65.54 | 2019 | |
| Lundbeck LLC | $62.88 | 2024 | Vyepti |
| Upsher-Smith Laboratories LLC | $60.64 | 2019-2020 | |
| Genentech USA, INC. | $58.76 | 2020-2024 | Ocrevus Zunovo, Ocrevus |
| Alexion Pharmaceuticals, INC. | $50.17 | 2019-2025 | Ultomiris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $45.07 | 2025 | Lumryz |
| Acadia Pharmaceuticals INC | $30.55 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $26.10 | 2024 | Austedo Xr |
| Neurelis, INC. | $23.59 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.06 | 2022 | |
| Bausch Health US, LLC | $21.99 | 2019 | |
| Acorda Therapeutics, INC | $13.72 | 2023 | Inbrija |
| Novartis Pharmaceuticals Corporation | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Wilbanks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.